| Drug ID: | Drug80 |
|---|---|
| Drug Name: | Curcumin |
| CID: | 969516 |
| DrugBank ID: | DB11672 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT00889161, , NCT04713631 |
| Molecular Formula: | C21H20O6 |
| Molecular Weight: | 368.4 g/mol |
| Isomeric SMILES: | COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O |
| Synonyms: | curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Gelbwurz; Haldar; Curcumin I; Souchet |
| Phase 0: | 11 |
| Phase 1: | 38 |
| Phase 2: | 67 |
| Phase 3: | 23 |
| Phase 4: | 14 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt675 | 969516 | Curcumin | 4843 | NOS2 | Homo sapiens (human) | None | |
| dt676 | 969516 | Curcumin | 765 | CA6 | Homo sapiens (human) | None | |
| dt677 | 969516 | Curcumin | 1576 | CYP3A4 | Homo sapiens (human) | None | |
| dt678 | 969516 | Curcumin | 4318 | MMP9 | Homo sapiens (human) | None | |
| dt679 | 969516 | Curcumin | 1789 | DNMT3B | Homo sapiens (human) | None | |
| dt680 | 969516 | Curcumin | 1786 | DNMT1 | Homo sapiens (human) | None | |
| dt681 | 969516 | Curcumin | 351 | APP | Homo sapiens (human) | None | |
| dt682 | 969516 | Curcumin | 759 | CA1 | Homo sapiens (human) | None | |
| dt683 | 969516 | Curcumin | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt684 | 969516 | Curcumin | 5594 | MAPK1 | Rattus norvegicus (Norway rat) | 11981161 | Curcumin inhibits the reaction [tetracaine results in increased phosphorylation of MAPK1 protein] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02683759 | Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis | PHASE3 | UNKNOWN | Asian Institute of Gastroenterology, India | Ulcerative Colitis | DIETARY_SUPPLEMENT: Bio-enhanced Curcumin Soft Ge… | Details |
| NCT02683733 | Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis | PHASE3 | UNKNOWN | Asian Institute of Gastroenterology, India | Ulcerative Colitis | DIETARY_SUPPLEMENT: Bio-enhanced Curcumin Soft Ge… | Details |
| NCT01320436 | Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis | PHASE3 | COMPLETED | Sheba Medical Center | Ulcerative Colitis | DIETARY_SUPPLEMENT: Curcumin|DRUG: 5-aminosalicyl… | Details |
| NCT03122613 | Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis | None | TERMINATED | Chinese University of Hong Kong | Ulcerative Colitis in Remission | DIETARY_SUPPLEMENT: Curcumin|DRUG: Placebo | Details |
| NCT04713631 | Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease | PHASE2 | RECRUITING | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Crohn's Disease | DRUG: Artesunate|DRUG: Curcumin|DRUG: Placebo A|D… | Details |
| NCT06867939 | A Pilot Study of Curcumin (Soloways in Patients With Inflammatory Bowel Disease Homozygous for the IL-10 Variant | Not Available | Not recruiting | S.LAB (SOLOWAYS) | Inflamatory Bowel Disease | Dietary Supplement: liposomal curcumin;Dietary Su… | Details |
| RBR-89q4ydz | Effect of supplementation with Curcuma Longa (extract) and Piperine on inflammatory markers, oxidative stress and glycoxidation in patients with Inflammatory Bowel Disease treated at a Teaching Hospital in Alagoa | Not Available | Not Recruiting | Universidade Federal de Alagoas | Inflammatory Bowel Disease | This is a double-blind randomized clinical trial.… | Details |
| NCT04879810 | Pilot Clinical Trial Investigating the Ability of Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease (IBD) | Not Available | Not recruiting | University of Louisville | Irritable Bowel Disease | Procedure: Sigmoidoscopy and biopsy, blood work | Details |
| JPRN-UMIN000015770 | Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease. - Exploratory study for effects of highly bioavailable curcumin on Crohn's disease. | Not Available | Not Recruiting | Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease Research | Crohn's disease (180 <= CDAI < 450) … | Standard therapy for Crohn's disease (Pentasa… | Details |
| NCT00889161 | Curcumin in Pediatric Inflammatory Bowel Disease | PHASE1 | COMPLETED | Seattle Children's Hospital | Inflammatory Bowel Disease|Ulcerative Colitis|Cro… | DRUG: Curcumin | Details |
| NCT05761327 | Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis | None | COMPLETED | Ardahan University | Ulcerative Colitis | OTHER: Mediterranean Diet|DIETARY_SUPPLEMENT: Cur… | Details |
| NCT02277223 | Curcumin in Pediatric Ulcerative Colitis | PHASE3 | WITHDRAWN | Schneider Children's Medical Center, Israel | Ulcerative Colitis | DIETARY_SUPPLEMENT: Curcumin|DRUG: Placebo | Details |
| NCT03500653 | Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab | None | UNKNOWN | Henit Yanai | Inflammatory Bowel Diseases | DIETARY_SUPPLEMENT: Curcumin|DIETARY_SUPPLEMENT: … | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S05 | Angiogenesis | cell proliferation; vascular permeability | ozanimod | The bioactive lipid S1P has been shown to activate NF-κB an… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Curcumin ameliorates DSS‑induced colitis in mice by regulating the Treg/Th17 si…
PMID: 33179078
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Curcumin has a therapeutic effect on ulcerative colitis, but the underlying mechanism has yet to be elucidated. The aim of the present study was to c…
Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endosc…
PMID: 32889959
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: The aim of this study was to assess the efficacy and safety of a novel, hydrophilic, bioenhanced curcumin (BEC) as add-on therap…
Curcumin Nanocrystal/pH-Responsive Polyelectrolyte Multilayer Core-Shell Nanopa…
PMID: 32701266
Year: 2020
Relationship Type:
Treatment
Score: 6.5
In this study, we developed oral core-shell nanoparticles composed of curcumin nanocrystals in the core and chitosan/alginate multilayers in the shel…
Anti-Ulcerative Effect of Curcumin-Galactomannoside Complex on Acetic Acid-Indu…
PMID: 32240451
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the mucosa and submucosa of colon. The pathogenesis of ulcerative coliti…
The effect of curcumin supplementation on clinical outcomes and inflammatory ma…
PMID: 31802559
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Curcumin has anti-inflammatory properties. The aim of this study was to evaluate the effect of curcumin on improvement of the di…
Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta-analysis of…
PMID: 31696975
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIM: Aminosalicylic acids are recognized to be the first-line treatment options for ulcerative colitis. Currently, the effectiveness o…
Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn'…
PMID: 31470175
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Recurrence of Crohn's disease (CD) after surgery is a major concern. Curcumin has anti-inflammatory properties and induces endos…
Efficacy and safety of curcumin in primary sclerosing cholangitis: an open labe…
PMID: 31131678
Year: 2019
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Golimumab has an established exposure-response relationship in patients with ulcerative colitis [UC]. However, the association …
Curcumin induces mild anemia in a DSS-induced colitis mouse model maintained on…
PMID: 31026259
Year: 2019
Relationship Type:
Association
Score: 6.5
OBJECTIVE: Inflammatory bowel disease (IBD) is a chronic, autoimmune, gastrointestinal disorder. Canada has one of the highest prevalence and incid…
Curcumin and Intestinal Inflammatory Diseases: Molecular Mechanisms of Protecti…
PMID: 31003422
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Intestinal inflammatory diseases, such as Crohn's disease, ulcerative colitis, and necrotizing enterocolitis, are becoming increasingly prevalent. Wh…
The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and …
PMID: 30132960
Year: 2018
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Curcuminoids are polyphenols with documented anti-inflammatory activity and has been shown to improve the symptoms of several inflammator…
The clinical efficacy of curcumin-containing nutraceuticals: An overview of sys…
PMID: 29890252
Year: 2018
Relationship Type:
Adverse Effect
Score: 6.3
BACKGROUND: The clinical efficacy of curcumin-containing nutraceuticals (e.g. turmeric preparations, curcumin, curcuminoids) for a range of condition…
Facile fabrication of bowl-shaped microparticles for oral curcumin delivery to …
PMID: 29751345
Year: 2018
Relationship Type:
Treatment
Score: 6.3
Oral microparticles (MPs) have been considered as promising drug carriers in the treatment of ulcerative colitis (UC). Here, a facile strategy based …
Effects of curcumin plus Soy oligosaccharides on intestinal flora of rats with …
PMID: 28838334
Year: 2017
Relationship Type:
Treatment
Score: 6.3
To explore the therapeutic effect of curcumin (Cur) and soybean oligosaccharides (SBOS) on ulcerative colitis (UC) through testing the intestinal flo…
Comparison of remicade to curcumin for the treatment of Crohn's disease: A syst…
PMID: 28735823
Year: 2017
Relationship Type:
Treatment
Score: 6.3
OBJECTIVE: The aim of this study was to review the literature to assess if there is evidence to support the use of Curcumin as a safe complementary t…
Structure-Activity Relationship of Curcumin: Role of the Methoxy Group in Anti-…
PMID: 28513174
Year: 2017
Relationship Type:
Association
Score: 6.3
Curcumin, a dietary compound from turmeric, has beneficial effects on inflammatory diseases such as inflammatory bowel disease. Most previous studies…
Biological activities of curcuminoids, other biomolecules from turmeric and the…
PMID: 28417091
Year: 2016
Relationship Type:
Treatment
Score: 6.3
In recent years, several drugs have been developed deriving from traditional products and current drug research is actively investigating the possibl…
Development and characterization of anti-inflammatory activity of curcumin-load…
PMID: 28040561
Year: 2017
Relationship Type:
Association
Score: 6.3
This research addresses the development and in vitro evaluation of a microparticulate system intended for intestine-targeted delivery of curcumin (CR…
Mucoadhesive microparticulates based on polysaccharide for target dual drug del…
PMID: 27239905
Year: 2016
Relationship Type:
Treatment
Score: 6.3
In this work, thiolated chitosan/alginate composite microparticulates (CMPs) coated by Eudragit S-100 were developed for colon-specific delivery of 5…
A combined omics approach to evaluate the effects of dietary curcumin on colon …
PMID: 26437580
Year: 2016
Relationship Type:
Mechanism
Score: 6.3
The aim of this study was to provide insight into how curcumin reduces colon inflammation in the Mdr1a(-/-) mouse model of human inflammatory bowel d…